Fox Chase Therapeutics Discovery, Inc. (formerly known as Fox Chase Chemical Diversity Center) Announces That It Has Been Awarded a Phase II STTR grant from the National Institutes of Health (NIAID) with Prof. Robert Ricciardi of the University of Pennsylvania
Doylestown, PA. August 2, 2024 – Fox Chase Therapeutics Discovery, Inc. is pleased to announce it has been awarded a Phase II STTR grant from the National Institutes of Health (NIAID) with Prof. Robert Ricciardi of the University of Pennsylvania entitled “Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum” (R42AI162385-03).